March 2017 - Cancer Currents Blog
- Blinatumomab Extends Survival for Patients with Advanced ALL
Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.
- Targeted Cancer Drug May Also Help Protect Fertility, Study Suggests
Findings from a new study in mice suggest that a class of targeted cancer drugs may have another use in some younger women being treated for cancer: preserving their fertility.
- Colorectal Cancer Incidence Rising in Young Adults: An Interview with Drs. Philip Rosenberg and William Anderson
Drs. Philip Rosenberg and William Anderson of NCI discuss a recent study on which they were coauthors that reported an increase in colorectal cancer incidence among adults under age 50 in the United States.
- Stem-Cell Based Tool May Help Measure Heart Toxicity of Cancer Drugs
Researchers have used adult stem cells to create a tool for ranking how toxic a group of cancer drugs, called tyrosine kinase inhibitors, are to human heart cells. Such a test could potentially identify toxic side effects earlier in the drug development process.
- Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors
Using a new tool for editing genomes, known as CRISPR, researchers have genetically engineered immune cells and improved the ability of these cells to kill cancer cells in mice.
- FDA Approves New Use for Lenalidomide in Multiple Myeloma
The FDA has approved lenalidomide for use as a maintenance therapy in patients with multiple myeloma who have undergone an autologous stem cell transplant, to help keep the cancer from coming back.
- Putting the Cancer Patient Front and Center: An Interview with NCI’s Dr. Paul Jacobsen
NCI’s Dr. Paul Jacobsen discusses NCI’s Healthcare Delivery Research Program and its role in advancing innovative research to improve the delivery of cancer care.
- Study Shows Platelets Can Deliver Immunotherapy, Reduce Tumor Regrowth
In experiments in mice, researchers show platelets linked to an immunotherapy drug can help eliminate residual cancer cells that remain after surgery. The engineered platelets may also prevent leftover cancer cells from spreading.